Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL0911 for prevention of chemotherapy-induced thrombocytopenia
CTR20222219Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of QL0911 in chemotherapy-induced thrombocytopenia (CIT), sponsored by Qilu Pharmaceutical. Started Dec 2022; status: completed.
02
Drugs
QL0911
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on CTR20222219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222219.